BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19243056)

  • 1. Superparamagnetic iron oxide-enhanced liver MRI with SHU 555 A (RESOVIST): New protocol infusion to improve arterial phase evaluation--a prospective study.
    Grazioli L; Bondioni MP; Romanini L; Frittoli B; Gambarini S; Donato F; Santoro L; Colagrande S
    J Magn Reson Imaging; 2009 Mar; 29(3):607-16. PubMed ID: 19243056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
    Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
    Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dynamic and static MRI using superparamagnetic MRI contrast medium Resovist for visualizing primary and secondary liver tumors].
    Vogl TJ; Schwarz W; Hammerstingl R; Kümmel S; Balzer JO; Mack MG; Diebold T; Balzer T; Shamsi K; Bechstein WO; Schrem H; Neuhaus P; Felix R
    Rofo; 1997 Sep; 167(3):264-73. PubMed ID: 9376555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [T1-weighted dynamic MRI with new superparamagnetic iron oxide particles (Resovist): results of a phantom study as well as 25 patients].
    Müller M; Reimer P; Wiedermann D; Allkemper T; Marx C; Tombach B; Rummeny EJ; Shamsi K; Balzer T; Peters PE
    Rofo; 1998 Mar; 168(3):228-36. PubMed ID: 9551108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced mr imaging.
    Kim YK; Kim CS; Kwak HS; Lee JM
    J Magn Reson Imaging; 2004 Nov; 20(5):826-37. PubMed ID: 15503325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular lesions with increased iron uptake on superparamagnetic iron oxide-enhanced magnetic resonance imaging in cirrhosis or chronic hepatitis: comparison of four magnetic resonance sequences for lesion conspicuity.
    Tanabe M; Ito K; Shimizu A; Fujita T; Onoda H; Yamatogi S; Washida Y; Matsunaga N
    Magn Reson Imaging; 2009 Jul; 27(6):801-6. PubMed ID: 19144487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging.
    Lutz AM; Willmann JK; Goepfert K; Marincek B; Weishaupt D
    Radiology; 2005 Nov; 237(2):520-8. PubMed ID: 16192317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of liver lesions with gadolinium-enhanced VIBE sequence in comparison with SPIO-enhanced MRI].
    Heim P; Steiner P; Schoder V; Dieckmann C; Kuhlencordt R; Adam G
    Rofo; 2003 Oct; 175(10):1376-83. PubMed ID: 14556107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US.
    Vogl TJ; Schwarz W; Blume S; Pietsch M; Shamsi K; Franz M; Lobeck H; Balzer T; del Tredici K; Neuhaus P; Felix R; Hammerstingl RM
    Eur Radiol; 2003 Feb; 13(2):262-72. PubMed ID: 12598989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-liver contrast and subjective tumor conspicuity of respiratory-triggered T2-weighted fast spin-echo sequence compared with T2*-weighted gradient recalled-echo sequence for ferucarbotran-enhanced magnetic resonance imaging of hepatic malignant tumors.
    Ishiyama K; Hashimoto M; Izumi J; Watarai J; Shibata S; Sato T; Yamamoto Y
    J Magn Reson Imaging; 2008 Jun; 27(6):1322-6. PubMed ID: 18504744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging.
    Lee JM; Kim CS; Youk JH; Lee MS
    Korean J Radiol; 2003; 4(1):9-18. PubMed ID: 12679629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical results with Resovist: a phase 2 clinical trial.
    Reimer P; Rummeny EJ; Daldrup HE; Balzer T; Tombach B; Berns T; Peters PE
    Radiology; 1995 May; 195(2):489-96. PubMed ID: 7724772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative assessment of iron-oxide-enhanced magnetic resonance imaging of the liver: Vessel isointensity is a potential characteristic of liver hemangiomas on late T1-weighted images.
    Schmitz SA; Nikolova A; O'Regan D; Albrecht T; Hohmann J; Wolf KJ
    Acta Radiol; 2006 Sep; 47(7):634-42. PubMed ID: 16950695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant hepatic tumor detection with ferumoxide-enhanced magnetic resonance imaging: is chemical-shift-selective fat suppression necessary for fast spin-echo sequence?
    Goshima S; Kanematsu M; Matsuo M; Kondo H; Kako N; Yokoyama R; Hoshi H; Moriyama N
    J Magn Reson Imaging; 2004 Jul; 20(1):75-82. PubMed ID: 15221811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superparamagnetic iron oxide (SPIO)-enhanced liver MRI with ferucarbotran: efficacy for characterization of focal liver lesions.
    Namkung S; Zech CJ; Helmberger T; Reiser MF; Schoenberg SO
    J Magn Reson Imaging; 2007 Apr; 25(4):755-65. PubMed ID: 17335040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: a potential new sign for characterization of liver lesions.
    Mergo PJ; Helmberger T; Nicolas AI; Ros PR
    AJR Am J Roentgenol; 1996 Feb; 166(2):379-84. PubMed ID: 8553952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
    Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
    Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Magnetic resonance imaging of hepatic focal lesions: dynamic contrastographic evaluation with gadolinium versus reticulo-endothelial hepato-specific contrast media].
    Di Cesare E; Cariello G; Barile A; Sabatini M; Michelini O; Erriquez D; Masciocchi C
    Radiol Med; 2000 Oct; 100(4):245-50. PubMed ID: 11155451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of SPIO-enhanced T1- and T2-weighted images for the differentiation of liver lesions: an ROC analysis].
    Stroszczynski C; Gaffke G; Gretschel S; Rambow A; Jost D; Schlecht I; Schneider U; Schicke B; Hohenberger P; Gebauer B; Felix R
    Rofo; 2003 Oct; 175(10):1368-75. PubMed ID: 14556106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography.
    Kim YK; Kwak HS; Han YM; Kim CS
    J Comput Assist Tomogr; 2007; 31(5):702-11. PubMed ID: 17895780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.